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Abstract
Background: The impact of pregnancy on the clinical course of acute hepatitis B (AHB) is still largely unclear,
mainly because most studies have not included matched controls. This study was conducted to investigate the
clinical features and outcome of AHB in pregnancy using matched controls.
Methods: Consecutive AHB inpatients who were admitted to Jinan Infectious Disease Hospital, Jinan, between
January 2006 and December 2010 were evaluated and followed. Demographic data, clinical manifestations, and
results of laboratory tests were compared between pregnant patients and age and sex matched non-pregnant
patients at admission, discharge, and final follow-up.
Results: A total of 618 AHB inpatients were identified during the study period. 22 pregnant patients and 87 age
and sex matched non-pregnant patients were enrolled in this study. Prodromal fever was less common (0% vs.
20.7%, P = 0.02), serum alanine aminotransferase levels were significantly lower, and HBsAg > 250 IU/mL rate and
serum bilirubin levels were significantly higher in pregnant patients than in non-pregnant patients. After a mean
(range) of 7(5.2-8.3) months follow-up, 18.2% pregnant patients and 4.6% non-pregnant patients were still HBsAg
positive (P = 0.03). For pregnant patients, the relative risk (95% confidence interval) of HBsAg positive at the end of
follow-up was 4.6 (1.1-20.2). The median (95% confidence interval) days of HBsAg seroclearance form disease onset
in pregnant and non-pregnant patients were 145.0 (110.5-179.5) and 80.0 (62.6-97.4), respectively.
Conclusions: The HBsAg loss and seroconversion were delayed and lower in pregnant patients. Pregnancy might
be a possible risk of chronicity following acute HBV infection.
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Background
It is well-known that acute hepatitis B virus (HBV)
infection in adults is usually self-limiting, of which only
5%-10% develop to chronic HBV infection, and about
1% progress to acute liver failure [1]. However, in certain
special populations, such as pregnant women, the clinical
course of acute hepatitis B (AHB) is still largely unclear.
Although a few studies have investigated the impact of
pregnancy on AHB, few of them included matched con-
trols [2-8]. Age, sex, and host immunity status are import-
ant factors influencing the clinical manifestation and
outcome of acute HBV infection [9]. Clinical features and
HBV serological outcome in pregnant AHB patients, such
as hepatitis B surface antigen (HBsAg) loss and serocon-
version, have not fully been elucidated.
The clinical presentation and natural history of HBV
infection is mediated through complex interactions be-
tween the virus and the host immune response [10]. In
acute HBV infection, both host innate immunity and
HBV specific adaptive immunity play important roles in
viral clearance [10,11]. Impaired immunity due to vari-
ous causes may influence the course of AHB [9,12-14].
During pregnancy, the maternal immune system is al-
tered to tolerate the genetically different fetus, and hor-
monal factors may also play a significant role in altering
immune regulation or viral replication [15]. An early
study by Mohite et al. reported that the T cell response
to HBsAg was weaker in pregnant women than in adults
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males and non-pregnant females [16]. So, immunological
response to acute HBV infection, and consequently the
clinical course of AHB in pregnant women may differ
from those in the general population [16].
The aim of this study was to investigate the clinical
features and outcome of AHB in pregnancy.
Methods
Study design and population
The present study was performed in the Jinan Infectious
Disease Hospital, the only hospital in the Jinan area
which is in charge of the diagnosis and treatment of the
35 notifiable infectious diseases of China. This study is
part of a hospital-based prospective investigation to study
the natural history of acute HBV infection that was con-
ducted in the hospital,in which all inpatients with con-
firmed AHB between January 2006 and December 2010
were included and followed. The study was approved by
the hospital ethics committee, and written informed con-
sent for participation was obtained from each study par-
ticipant or their next of kins.
The diagnosis of AHB was based on discrete onset
of symptoms (such as: fever, loss of appetite, fatigue,
and dark urine), jaundice, elevated serum alanine ami-
notransferase (ALT) or aspartate aminotransferase (AST)
levels, detection of high-titer IgM antibody to hepa-
titis core antigen (anti-HBc), and compatible clinical
history [17,18].
Patients with a history or other evidence of liver dis-
ease other than AHB, or with alcohol consumption of
more than 20 g/day for more than five years were ex-
cluded. All patients were to be followed for at least 6 months.
In general, follow-up schedule was 1 month, 3 months,
and 6 months after discharge.
In this study, the clinical manifestation, biochemical
and virological parameters, and outcome of pregnant
AHB patients were compared with those of sex and age
matched non-pregnant AHB patients.
Study variables
The variables analyzed in this study included demographic
data, prodromal signs and symptoms, complications, serum
biochemical parameters, HBV serological marker, HBV
DNA levels at admission, discharge and final follow-up.
Days from disease onset to patient’s hospital admis-
sion, duration of hospitalization and follow-up were
also analyzed.
Upon entry to the hospital, all patients were inter-
viewed by trained physicians. The details of information
collection and laboratory measurements were previously
described [19,20]. The transmission routes and risk fac-
tors of HBV infection were recorded using a structured
questionnaire. In general, biochemical parameters, HBV
serological markers, and HBV DNA levels, were measured
at least once at admission, before discharge, and at each
visit during follow-up. A form designed for this investi-
gation was used to record the information collected at
every visit.
For patients with jaundice, prodromal manifestations
were defined as signs or symptoms occurring in the 1–10
days before onset of icterus (prodromal period). For pa-
tients without jaundice, prodromal manifestations were
defined as signs or symptoms occurring in the 1–10 days
before diagnosis of hepatitis or the hospital admission.
Prodromal signs and symptoms analyzed in this study
included fever, loss of appetite, fatigue. Prodromal fever
were defined in 2 different ways: patients reporting a
measured fever ≥ 37.5°C during prodromal period; any
fever (measured or subjective) during prodromal period
[21,22]. Jaundice referred to measured serum total bili-
rubin > 25 μmol/L at admission. HE was diagnosed and
classified as previously described [23]. The presence of
ascites was evaluated using B ultrasonography.
Clinical outcome included occurrence of fulminant
hepatitis, clinical recovery (defined as relief of signs and
symptoms and normalization of ALT levels), and mortality.
HBV virological and serological outcome included un-
detectable HBV DNA, HBsAg loss, HBsAg seroconversion
(i.e. loss of HBsAg and appearance of anti-HBsAg anti-
bodies), hepatitis B e antigen (HBeAg) seroconversion
(i.e. loss of HBeAg and appearance of anti-HBeAg anti-
bodies). Chronic HBV infection was defined as persistent
of HBsAg in serum with or without detectable serum HBV
DNA after disease onset of more than 6 months [24].
AHB with evidence of coagulation abnormality (INR ≥
1.5) and encephalopathy was diagnosed as acute fulminant
hepatitis [23].
Statistical analysis
Clinical parameters were evaluated using the chi-squared
test for discrete variables and the t test or Mann–Whitney
U test for continuous variables. A Kaplan–Meier estimate
was performed to compare the fraction of patients remain
HBsAg positive and days of HBsAg seroclearance after
disease onset, and p values were calculated using log-rank
test. For all tests, a P value of less than 0.05 was consid-
ered significant. All data analyses were performed using
SPSS v. 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Among a total of 618 inpatients diagnosed with AHB
during the study period, 22 pregnant patients were en-
rolled into the pregnant group. The mean ± SD and me-
dian (min-max) age of the AHB in pregnant patients
was 22.7 ± 1.9 years and 22 (21–28) years, respectively.
87 female non-pregnant patients between 21 and 28 years
of age were enrolled in the control group.
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Demographic characteristics of AHB in pregnancy
The demographic characteristics of the two groups are
summarized in Table 1. Most pregnant AHB patients
were from rural areas of Shandong Province (90.9%).
The mean length from onset of signs and symptoms to
hospital admission was similar between the two groups.
Of the 22 pregnant AHB patients, 8 were in the first tri-
mester, 8 were in the second trimester, and 6 were in the
third trimester of pregnancy. The mean length (min-
max) of pregnancy was 17.3 (7–31) weeks. 72.5% of the
patients ever exposed to at least one potential risk factor
of acute HBV infection. No pregnant patients had gesta-
tional diabetes mellitus.
Clinical and biochemical characteristics of AHB in pregnancy
As shown in Table 2, fever was less frequent, and jaun-
dice was more frequent in pregnant patients than in
non-pregnant patients.
The biochemical data of pregnant and non-pregnant
AHB patients at admission, discharge, and final follow-up
are summarized in Table 3. At admission, the median
ALT levels of pregnant patients were significantly lower
than that of non-pregnant patients. The median total
serum bilirubin level was higher in pregnant patients than
in non-pregnant patients. The median serum albumin and
gamma-glutmyltransferase (GGT) levels were both signifi-
cantly lower in pregnant patients than in non-pregnant
patients (P < 0.001).
After a mean (min-max) of 27.8 (5–69) day’s support-
ive treatment, clinical manifestations and biochemical
data of all patients were significantly improved.
After a mean (min-max) of 7 (5.2-8.3) months follow-
up, ALT and bilirubin normalization rate were similar be-
tween the two groups. However, the median ALT, serum
albumin and GGT levels were still significantly lower in
pregnant patients than in non-pregnant patients.
HBV virological and serological outcome of AHB in
pregnancy
The HBV virological and serological biochemical data of
pregnant and non-pregnant AHB patients at admission,
discharge, and final follow-up are summarized in Table 4.
At admission, the median HBV DNA level was similar be-
tween the two groups (P = 0.69), and the HBV DNA >
1000 copies/mL rate was also similar between the two
groups. The HBsAg positive (>0.05 IU/mL) rate was simi-
lar between the two groups. The HBsAg > 250 IU/mL rate
and HBeAg positive rate were significantly higher in preg-
nant than in non-pregnant patients.
At discharge, the HBsAg positive rate was significantly
higher in pregnant patients than in non-pregnant pa-
tients, whereas virological and other serological parame-
ters were similar between the two groups.
At final follow-up, the HBsAg positive rate was sig-
nificantly higher in pregnant patients than in non-pregnant
patients. 18.2% pregnant patients and 4.6% non-pregnant
patients developed chronic HBV infection. For pregnant pa-
tients, the relative risk (95% confidence interval) of HBsAg
positive at the end of follow-up was 4.6 (1.1-20.2). The
Kaplan–Meier estimates showed the median (95% confi-
dence interval) days of HBsAg seroclearance form dis-
ease onset in pregnant and non-pregnant patients
were 145.0 (110.5-179.5) and 80.0 (62.6-97.4), respect-
ively (Figure 1).
Table 1 Demographics and the risk factors exposed
within 6 months before onset of AHB: comparison of
pregnant and non-pregnant patients
Variables Non-pregnant AHB
patients N = 87
Pregnant AHB
patients N = 22
P
Age (years) 23.3 ± 2.6 22.7 ± 1.9 0.18
Residence 0.001
Urban 42 (48.3%) 2 (9.1%)




10.9 ± 7.5 10.6 ± 4.1 0.78
Days of stay in
hospital
28.7 ± 10.3 24.7 ± 7.4 0.09
Weeks of pregnancy NA 17.3 ± 8.7 NA
Potential risk factors 0.17
Spouse with HBV
infection
8 (9.2%) 6 (27.3%)
Other family members
with HBV infection
3 (3.4%) 1 (4.5%)
Risk sex behavior 32 (36.8%) 3 (13.6%)
Invasive medical
procedure
12 (13.8%) 4 (18.2%)
Body care 8 (9.2%) 2 (9.1%)
Unknown 24 (27.6%) 6 (27.3%)
More than one factor 35 (55.6%) 7 (45.7%) 0.40
NOTE. Data are expressed as mean ± SD or n (%) of patients; AHB, acute
hepatitis B.
Table 2 Symptoms,signs, and complications of pregnant
and non-pregnant AHB patients
Variables Non-pregnant AHB
patients N = 87 (%)
Pregnant AHB
patients N = 22 (%)
P
Fever 18 (20.7) 0 (0) 0.02
Fatigue 65 (74.7) 15 (68.2) 0.54
Loss of appetite 70 (80.5) 14 (63.6) 0.08
Jaundice 56 (62.2) 19 (95.4) 0.003
Ascites 1 (1.15) 0 (0) 0.61
Encephalopathy 1 (1.15) 0 (0) 0.61
NOTE. AHB, acute hepatitis B.
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Discussion
Just as it is generally accepted that pregnancy does not
alter clinical recovery and mortality of AHB [25], the
present study also did not find any significance differ-
ence on AHB mortality and occurrence of flulminant
hepatitis between pregnant and non-pregnant patients.
Clinical recovery, defined as relief of signs and symp-
toms, and normalization of ALT, was also similar be-
tween pregnant and non-pregnant females. However, the
present study did reveal certain clinical and serological
features of AHB during pregnancy.
Most of the patients in the present study were symp-
tomatic (83.8%), whose signs and symptoms included
prodromal fever, fatigue, and loss of appetite. Fever was
significantly less common (0% vs. 20.7%, P = 0.02) in
pregnant than in non-pregnant AHB patients, whereas
the presence of other symptoms, such as fatigue and
loss of appetite, were similar between the two groups.
This finding may be partly explained by the “febrile
hyporesponsiveness” phenomenon during pregnancy
[26]. The febrile response is a significant contributor
to the pathogenesis, clinical presentation and outcome
of many illnesses and diseases [21]. During pregnancy,
febrile response is suppressed by the following potential
mechanisms: suppression of pro-inflammatory processes,
augmentation of anti-inflammatory processes, and alter-
ations in steroid hormones [21]. The suppressed febrile re-
sponse during pregnancy can lead to a compromised
ability to fight infection while it could be beneficial to the
mother and the fetus. Whether the altered immunity
Table 3 Biochemical data in pregnant and non-pregnant AHB patients at admission, discharge and final follow-up
Variables Non-pregnant AHB patients N = 87 Pregnant AHB patients N = 22 P
At admission
Days from disease onset to examination 11.8 ± 7.3 11.3 ± 4.1 0.70
ALT(IU/L) 1237 (274–3615) 1025 (285–1797) 0.039
ALT > 1600 IU/L 27 (31.0%) 1 (4.5%) 0.01
Bilirubin(μmol/L) 66.4 (8.2-549.7) 140 (29.6-289.1) 0.005
Bilirubin > 25 μmol/L 69 (79.3%) 22 (100%) 0.02
Albumin(g/L) 39.0 (28–66) 33.0 (23.0-42.3) < 0.001
Albumin < 35 g/L 12 (13.8%) 14 (63.6%) < 0.001
GGT(IU/L) 95 (22–425) 32.5 (21–159) < 0.001
GGT > 64 IU/L 68 (78.1%) 4 (18.2%) < 0.001
At discharge
Days from disease onset to examination 38.6 ± 11.9 34.2 ± 7.1 0.11
ALT(IU/L) 28 (7–712) 17 (9–128) 0.004
ALT normalization 56 (64.4%) 20 (90.9%) 0.02
Bilirubin(μmol/L) 15.2 (4.2-212.5) 19.7 (8–61.4) 0.27
Bilirubin normalization 65 (74.7%) 17 (77.3%) 0.80
Albumin(g/L) 40.4 (32–48.4) 35 (30–38.8) < 0.001
Albumin normalization 85 (97.7%) 12 (54.5%) < 0.001
GGT(IU/L) 48.0 (10–227) 28.5 (12–93) < 0.001
GGT normalization 60 (69.0%) 20 (90.9%) 0.04
Final follow-up
Months from disease onset to examination 7.0 ± 0.8 6.9 ± 0.7 0.54
ALT(IU/L) 20 (5–68) 12 (6–37) 0.015
ALT normalization 83 (95.4%) 22 (100%) 0.31
Bilirubin(μmol/L) 12.1 (4.2-56) 13 (5–22) 0.47
Bilirubin normalization 83 (94.4%) 22 (100%) 0.31
Albumin(g/L) 43 (36–48.5) 39.5 (34–43.0) < 0.001
Albumin < 35 g/L 0 (0%) 3 (13.6%) < 0.001
GGT(IU/L) 37 (10–87) 20 (12–30) < 0.001
GGT normalization 80 (91.9%) 22 (100%) 0.17
NOTE. Data are expressed as mean ± SD, median(min-max), or n (%) of patients. AHB, acute hepatitis B; ALT, alanine aminotransferase; GGT, gamma-glutmyltransferase.
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during pregnancy affects HBV DNA replication and eradi-
cation is still inconclusive.
Several studies investigated the effect of pregnancy on
serum HBV DNA levels of pregnant women with chronic
HBV infection [27-29]. The study by Soderstrom et al. ob-
served increased serum HBV DNA levels in late pregnancy
or early post-partum [28]. But, Nguyen et al. reported that
the levels of HBV DNA and ALT during pregnancy were
highly variable [27]. Little information is available regard-
ing the virological and serological changes during acute
HBV infection in pregnant patients.
In the present study, the median HBV DNA levels and
HBV DNA undetectable rate were similar between preg-
nant and non-pregnant patients. HBV DNA and ALT
levels were highly variable in both groups.
We noted significant lower ALT levels in pregnant
women. A study on acute liver failure during pregnancy by
Bhatia et al. also observed significantly lower ALT levels in
pregnant women than in men and non-pregnant women
[30]. Elevated serum ALT levels or symptoms reflect the
T-cell-mediated HBV-specific immune response [10]. The
mild symptoms and relatively low ALT levels in pregnant
AHB patients indicate that HBV specific immunity in preg-
nancy may differ from those in the general population.
Interestingly, we noted a significantly higher HBsAg
levels and lower HBsAg severconversion rate in pregnant
patients than in non-pregnant patients. At admission and
discharge, the percent of HBsAg > 250 IU/mL in pregnant
patients was higher than that in non-pregnant patients.
Moreover, at final follow-up, about 7 months from disease
onset, 18.2% of the pregnant patients were still HBsAg
positive, a chronic HBsAg carrier state, whereas only 4.6%
of the non-pregnant patients were HBsAg positive. Also,
at final follow-up, the HBsAg seroconversion rate was sig-
nificantly lower in pregnant than in non-pregnant patients
(40.9% vs. 67.8%, P = 0.02). HBsAg levels reflect the host
immune control state and cccDNA levels in hepato-
cytes [31,32]. T-cells are markedly reduced during early
Table 4 HBV serological and virological data in pregnant and non-pregnant AHB patients at admission, discharge and
final follow-up
Variables Non-pregnant AHB patients N = 87 Pregnant AHB patients N = 22 P
At admission
Days from disease onset to examination 11.8 ± 7.3 11.3 ± 4.1 0.70
HBsAg positive 6 (93.1%) 22 (100%) 0.21
HBsAg > 250 IU/mL 45 (51.7%) 17 (77.3%) 0.03
HBsAg seroconversion 3 (3.44%) 0 (0%) 0.38
HBeAg positive 52 (59.8%) 19 (86.4%) 0.02
HBeAg seroconversion 33 (37.9%) 2 (9.1%) 0.01
HBV DNA (log10 copies/mL) 3.49 (3.0-7.14) 3.49 (3.0-4.93) 0.69
HBV DNA >1000 copies/mL 55 (63.2%) 17 (77.3%) 0.21
At discharge
Days from disease onset to examination 38.6 ± 11.9 34.2 ± 7.1 0.11
HBsAg positive 54 (62.1%) 19 (86.4%) 0.03
HBsAg > 250 IU/mL 19 (21.8%) 9 (40.9%) 0.07
HBsAg seroconversion 11 (12.6%) 0 (0%) 0.08
HBeAg positive 8 (9.2%) 3 (13.6%) 0.54
HBeAg seroconversion 72 (82.8%) 15 (68.2%) 0.13
HBV DNA >1000 copies/mL 11 (12.6%) 1 (4.5%) 0.28
Final follow-up
Months from disease onset to examination 7.0 ± 0.8 (5.2-8.3) 6.9 ± 0.7 (5.8-8.2) 0.54
HBsAg positive 4 (4.6%) 4 (18.2%) 0.03
HBsAg > 250 IU/mL 1 (1.1%) 1 (4.5%) 0.29
HBsAg seroconversion 59 (67.8%) 9 (40.9%) 0.02
HBeAg positive 1 (1.1%) 1 (4.5%) 0.29
HBeAg seroconversion 80 (91.9%) 19 (86.3%) 0.42
HBV DNA > 1000 copies/mL 1 (1.1%) 1 (4.5%) 0.29
NOTE. Data are expressed as mean ± SD,median (min-max), or n (%) of patients; HBV, hepatitis B virus; AHB, acute hepatitis B; HBsAg,hepatitis B surface antigen;
HBeAg, hepatitis e antigen.
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pregnancy up to the 20th week of gestation to reduce the
level of immunity [15]. Increased hormone levels during
pregnancy, including progesterone, estrogen and human
chorionic gonadotropin, have been shown to have a clear
suppressive effect on cell-mediated immunity [26]. This
status may indicate that the altered immunity status may
influence the eradication of HBV infected cells and the
production of HBsAg antibodies. This notion is supported
by the study of Mohite et al. which reported that the T cell
response to HBsAg in pregnant women with AHB was ab-
sent throughout the illness, whereas that in adult males
and non-pregnant females increased gradually after AHB
onset [16].
We also noted a significantly more frequent and severe
jaundice in pregnant women. At admission, hyperbiliru-
binemia was seen in all pregnant patients, and the total
bilirubin level was significantly higher in pregnant than
in non-pregnant patients. In acute hepatitis, serum total
bilirubin level usually correlates positively with severity of
liver injury [33]. However, we observed an inconsistence
of total bilirubin level with peak ALT levels, a sensitive in-
dicator of liver injury, in pregnant AHB patients. This in-
dicate hyperbilirubinemia in pregnant AHB patients might
be caused not only by intrahepatic inflammation, but pos-
sibly also by other factors influencing bilirubin clearance.
Serum albumin and UDP-glucuronosyltransferase(UGP)
are involved in bilirubin metabolism [34,35]. Significant
lower serum albumin level, a protein that transports bili-
rubin, were observed in our and other studies [34,36].
An animal study revealed decreased expression of UGP1A1
during pregnancy in rat liver [37]. Recent genome-wide
association studies indicated the UGP1A1 were important
genes in controlling serum bilirubin [35]. These results
might partially explained the inconsistence between
bilirubin concentration and ALT level in pregnant AHB
patients.
The serum GGT levels were also significantly lower in
pregnant patients. The serum GGT activity are lower in
normal pregnant women than in non-pregnant women
[36]. Hepatic synthesis of GGT could be inhibited by
hormone secretion during pregnancy [36].
The strong point of the present study is the use of
controls matched in age, sex, alcohol consumption, and
other factors which may influence the course of AHB,
with pregnant patients. Days from disease onset were
also comparable between the two groups. To our know-
ledge, this is the first study that investigated the course
of AHB during pregnancy with well matched controls.
There is a concern that 7 month follow up is too short.
However, according to current acute hepatitis B investiga-
tive guidelines, those still HBV DNA-positive or HBsAg-
positive are considered confirmed chronic carriers, and
should be counseled accordingly [17]. In fact, we followed
the patients for at least 1 year. For the pregnant AHB pa-
tients, none of them used antiviral therapy during follow-
up, 4 patients were still HBsAg positive after at least
12 month follow-up. However, among the 618 AHB pa-
tients, for those without pregnancy, a significant portion
of those still HBV DNA positive after 6 months of infec-
tion were treated with interferon or nucleotide analogues.
Also, this was a hospital-based study, most patients in this
study were symptomatic and relatively severe. The clinical
features and outcome of asymptomatic AHB in pregnancy
is not clear. To answer these questions, a large scaled
population based study is needed.
Conclusion
Although the clinical recovery of AHB differs little in
pregnant and non-pregnant patients, the HBsAg loss
and seroconversion is delayed and lower in pregnant pa-
tients. Pregnancy might be a possible risk of chronicity
following acute HBV infection. Further clinical and basic
studies are necessary to confirm the findings and to elu-
cidate the underlying mechanisms.
Abbreviations
AHB: Acute hepatitis B; ALT: Alanine aminotransferase; anti-HBc: Antibody
to hepatitis core antigen; AST: Aspartate aminotransferase; GGT:
Gamma-glutmyltransferase; HBsAg: Hepatitis B surface antigen;
HBV: Hepatitis B virus.
Competing interests
The authors declare that there are no competing interests.
Authors’ contributions
YH: acquisition of data, technical support; CS: acquisition of data; CL:
acquisition of data; SX: acquisition of data; DX: acquisition of data; LL:
acquisition of data; JY: acquisition of data; WL: acquisition of data; QL: study
concept and design, analysis and interpretation of data, drafting of the
Figure 1 Changes of the HBsAg status after disease onset.
Cumulative rates of HBsAg seroclearance, analyzed with the
Kaplan–Meier test.
Han et al. BMC Infectious Diseases 2014, 14:368 Page 6 of 7
http://www.biomedcentral.com/1471-2334/14/368
manuscript, study supervision. All authors read and approved the final
manuscript.
Acknowledgments
This study was funded by the Jinan Technology Development Projects
[2007095–3] and the 5th Quancheng Outstanding Medical Scholar Research
Fund.Thanks to Dr. Edward C. Mignot, Shandong University, for linguistic
advice.
Author details
1Department of Pharmacy, Qilu Hospital, Shandong University, Jinan, China.
2Division of Liver Disease, Jinan Infectious Disease Hospital, Shandong
University, Jinan, China. 3Unit of Disease Control Genome Medicine, Institute
of Medical Science, University of Tokyo, Tokyo, Japan.
Received: 3 March 2014 Accepted: 30 June 2014
Published: 3 July 2014
References
1. Liang TJ: Hepatitis B: the virus and disease. Hepatology 2009, 49(5 Suppl):
S13–S21.
2. Steven MM: Pregnancy and liver disease. Gut 1981, 22(7):592–614.
3. Cossart YE: The outcome of hepatitis B virus infection in pregnancy.
Postgrad Med J 1977, 53(624):610–613.
4. Nayak NC, Panda SK, Datta R, Zuckerman AJ, Guha DK, Madanagopalan N,
Buckshee K: Aetiology and outcome of acute viral hepatitis in pregnancy.
J Gastroenterol Hepatol 1989, 4(4):345–352.
5. Jaiswal SP, Jain AK, Naik G, Soni N, Chitnis DS: Viral hepatitis during
pregnancy. Int J Gynaecol Obstet 2001, 72(2):103–108.
6. Khuroo MS, Kamili S: Aetiology, clinical course and outcome of sporadic
acute viral hepatitis in pregnancy. J Viral Hepat 2003, 10(1):61–69.
7. Heijtink RA, Paulij W, Van Roosmalen M, Hellings JA, Niesters HG, Schalm
SW, Osterhaus AD: Characteristics of the early phase of chronicity in
acute hepatitis B infection. J Med Virol 1999, 57(4):331–336.
8. Sookoian S: Liver disease during pregnancy: acute viral hepatitis. Ann
Hepatol 2006, 5(3):231–236.
9. Hyams KC: Risks of chronicity following acute hepatitis B virus infection:
a review. Clin Infect Dis 1995, 20(4):992–1000.
10. Ratnam D, Visvanathan K: New concepts in the immunopathogenesis of
chronic hepatitis B: the importance of the innate immune response.
Hepatol Int 2008, 2(1):12–18.
11. Bertoletti A, Gehring AJ: The immune response during hepatitis B virus
infection. J Gen Virol 2006, 87(Pt 6):1439–1449.
12. Hadler SC, Judson FN, O’Malley PM, Altman NL, Penley K, Buchbinder S,
Schable CA, Coleman PJ, Ostrow DN, Francis DP: Outcome of hepatitis B
virus infection in homosexual men and its relation to prior human
immunodeficiency virus infection. J Infect Dis 1991, 163(3):454–459.
13. Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S: Influence of prior
HIV-1 infection on the development of chronic hepatitis B infection.
Eur J Clin Microbiol Infect Dis 2000, 19(3):237–239.
14. Fujiwara K, Yokosuka O, Kojima H, Kanda T, Saisho H, Hirasawa H, Suzuki H:
Importance of adequate immunosuppressive therapy for the recovery of
patients with “life-threatening” severe exacerbation of chronic hepatitis
B. World J Gastroenterol 2005, 11(8):1109–1114.
15. Navaneethan U, Al Mohajer M, Shata MT: Hepatitis E and pregnancy:
understanding the pathogenesis. Liver Int 2008, 28(9):1190–1199.
16. Mohite BJ, Rath S, Bal V, Kamat SA, Marathe SN, Zuckerman AJ, Kamat RS:
Mechanisms of liver cell damage in acute hepatitis B. J Med Virol 1987,
22(3):199–210.
17. Centers for Disease Control and Prevention: Guidelines For Viral Hepatitis
Surveillance And Case Management. Atlanta, GA: Centers for Disease
Control and Prevention; 2005. http://www.cdc.gov/hepatitis/PDFs/
2005Guidlines-Surv-CaseMngmt.pdf. Accessed January 6, 2013.
18. Sharif O, Krishnan PV, Thekdi AD, Gordon SC: Acute hepatitis B in an urban
tertiary care hospital in the United States: a cohort evaluation. J Clin
Gastroenterol 2013, 47(9):e87–e90.
19. Li Q, Li WW, Yang X, Fan WB, Yu JH, Xie SS, Liu L, Ma LX, Chen SJ, Kato N, Li
Q, Li WW, Yang X, Fan WB, Yu JH, Xie SS, Liu L, Ma LX, Chen SJ, Kato N:
Type 2 diabetes and hepatocellular carcinoma: A case–control study in
patients with chronic hepatitis B. Int J Cancer 2012, 131(5):1197–1202.
20. Li Q, Yu CH, Yu JH, Liu L, Xie SS, Li WW, Yang X, Fan WB, Gai ZT, Chen SJ,
Kato N: ABO Blood Group and the Risk of Hepatocellular Carcinoma:
A Case–control Study in Patients with Chronic Hepatitis B. PLoS ONE
2012, 7(1):e29928.
21. Ogoina D: Fever, fever patterns and diseases called ‘fever’–a review.
J Infect Public Health 2011, 4(3):108–124.
22. O’Grady NP, Barie PS, Bartlett JG, Bleck T, Carroll K, Kalil AC, Linden P, Maki
DG, Nierman D, Pasculle W, Masur H: Guidelines for evaluation of new
fever in critically ill adult patients: 2008 update from the American
College of Critical Care Medicine and the Infectious Diseases Society of
America. Crit Care Med 2008, 36(4):1330–1349.
23. Polson J, Lee WM: AASLD position paper: the management of acute liver
failure. Hepatology 2005, 41(5):1179–1197.
24. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45(2):507–539.
25. Jonas MM: Hepatitis B and pregnancy: an underestimated issue. Liver Int
2009, 29(Suppl 1):133–139.
26. Spencer SJ, Mouihate A, Galic MA, Pittman QJ: Central and peripheral
neuroimmune responses: hyporesponsiveness during pregnancy.
J Physiol 2008, 586(2):399–406.
27. Nguyen G, Garcia RT, Nguyen N, Trinh H, Keeffe EB, Nguyen MH: Clinical
course of hepatitis B virus infection during pregnancy. Aliment Pharmacol
Ther 2009, 29(7):755–764.
28. Soderstrom A, Norkrans G, Lindh M: Hepatitis B virus DNA during
pregnancy and post partum: aspects on vertical transmission. Scand J
Infect Dis 2003, 35(11–12):814–819.
29. Ter Borg MJ, Leemans WF, De Man RA, Janssen HL: Exacerbation of chronic
hepatitis B infection after delivery. J Viral Hepat 2008, 15(1):37–41.
30. Bhatia V, Singhal A, Panda SK, Acharya SK: A 20-year single-center experience
with acute liver failure during pregnancy: is the prognosis really worse?
Hepatology 2008, 48(5):1577–1585.
31. Sonneveld MJ, Zoutendijk R, Janssen HL: Hepatitis B surface antigen
monitoring and management of chronic hepatitis B. J Viral Hepat 2011,
18(7):449–457.
32. Chisari FV, Ferrari C: Hepatitis B virus immunopathogenesis. Annu Rev
Immunol 1995, 13:29–60.
33. Limdi JK, Hyde GM: Evaluation of abnormal liver function tests. Postgrad Med
J 2003, 79(932):307–312.
34. Billing BH, Black M: Bilirubin metabolism. Gut 1969, 10(4):250–254.
35. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T, Lin
JP, Van Duijn CM, Harris TB, Cupples LA, Uitterlinden AG, Launer L, Hofman
A, Rivadeneira F, Stricker B, Yang Q, O'Donnell CJ, Gudnason V, Witteman
JC: Genome-wide association meta-analysis for total serum bilirubin
levels. Hum Mol Genet 2009, 18(14):2700–2710.
36. Bacq Y, Zarka O, Brechot JF, Mariotte N, Vol S, Tichet J, Weill J: Liver
function tests in normal pregnancy: a prospective study of 103 pregnant
women and 103 matched controls. Hepatology 1996, 23(5):1030–1034.
37. Luquita MG, Catania VA, Pozzi EJ, Veggi LM, Hoffman T, Pellegrino JM,
Ikushiro S, Emi Y, Iyanagi T, Vore M, Mottino AD: Molecular basis of perinatal
changes in UDP-glucuronosyltransferase activity in maternal rat liver.
J Pharmacol Exp Ther 2001, 298(1):49–56.
doi:10.1186/1471-2334-14-368
Cite this article as: Han et al.: Clinical features and outcome of acute
hepatitis B in pregnancy. BMC Infectious Diseases 2014 14:368.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Han et al. BMC Infectious Diseases 2014, 14:368 Page 7 of 7
http://www.biomedcentral.com/1471-2334/14/368
